If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT02666001","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"http://","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":"true"},"PatientLevelData":"false","SharingIpd":"No","acronym":"","allocation":"Non-randomized","arm_groups":[{"arm_group_label":"Part 1 (BMS-663068+methadone)","arm_group_description":"Effect of multiple doses of BMS-663068, 600mg ER on the exposure of methadone","arm_type":"Experimental"},{"arm_group_label":"Part 2 (BMS-663068+buprenorphine and norbuprene)","arm_group_description":"Effect of multiple doses of BMS-663068, 600mg ER on the exposure of buprenorphine and norbuprenorphine","arm_type":"Experimental"}],"assignment":"Crossover Assignment","brief_summary":"The study is being conducted to assess the effect of multiple doses of BMS-663068 on the exposure of methadone in subjects on a stable dose of methadone, and the exposure of buprenorphine and norbuprenorphine in subjects on a stable dose of buprenorphine and norbuprenorphine.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:35:27","criteria":"Inclusion Criteria: 1.Signed Informed Consent 2.Target population: Subjects on methadone maintenance therapy (for inclusion in Part 1) or buprenorphine and norbuprenorphine maintenance therapy (for inclusion in Part 2), who have been reliably participating in an oral methadone or buprenorphine and norbuprenorphine program and who are on a stable dose for at least 30 days prior to study screening 3.Male and Female Subjects with body mass index of 18 to 34 kg/m2, inclusive 4.Women of child bearing potential (WOCBP) with negative serum or urine pregnancy test and must not be breastfeeding 5.Men and WOCBP must agree to follow instructions for contraception Exclusion Criteria: 1.History of any chronic or acute illness, gastrointestinal disease, smoking and alcohol abuse 2.Any Gastrointestinal (GI) surgery within 4 weeks of study drug administration that could affect its absorption 3.Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population. 4.History of allergy to any drugs, BMS-663068, HIV attachment inhibitors, or related compounds","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 1","display_phase_internal":"PHASE_1","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"32","exclusion":"","gender":"All","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"bf87e814-2eb4-5541-b1bb-dd2e2dd6a010","internal":{"content":null,"contentDigest":"75ff42274bdd838bd5054df7333e66ac","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: 1.Signed Informed Consent 2.Target population: Subjects on methadone maintenance therapy (for inclusion in Part 1) or buprenorphine and norbuprenorphine maintenance therapy (for inclusion in Part 2), who have been reliably participating in an oral methadone or buprenorphine and norbuprenorphine program and who are on a stable dose for at least 30 days prior to study screening 3.Male and Female Subjects with body mass index of 18 to 34 kg/m2, inclusive 4.Women of child bearing potential (WOCBP) with negative serum or urine pregnancy test and must not be breastfeeding 5.Men and WOCBP must agree to follow instructions for contraception Exclusion Criteria: 1.History of any chronic or acute illness, gastrointestinal disease, smoking and alcohol abuse 2.Any Gastrointestinal (GI) surgery within 4 weeks of study drug administration that could affect its absorption 3.Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population. 4.History of allergy to any drugs, BMS-663068, HIV attachment inhibitors, or related compounds","interventions":[{"arm_group_label":"Part 1 (BMS-663068+methadone)","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"Part 2 (BMS-663068+buprenorphine and norbuprene)","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"Part 1 (BMS-663068+methadone)","intervention_description":"Methadone","intervention_name":"Methadone","intervention_type":"Drug"},{"arm_group_label":"Part 2 (BMS-663068+buprenorphine and norbuprene)","intervention_description":"Buprenorphine and Norbuprenorphine","intervention_name":"Buprenorphine and Norbuprenorphine","intervention_type":"Drug"}],"interventional_subtype":"Other","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":[],"last_follow_up_date":"06/29/2016 00:00:00","links":[],"locations":[{"City":"Orlando","Latitude":"28.4588856","CountryDisplay":"United States","Longitude":"-81.3949264","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32809","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Overland Park","Latitude":"38.9221969","CountryDisplay":"United States","Longitude":"-94.6295394","Name":"GSK Investigational Site","StateDisplay":"Kansas","PostalCode":"66211","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"","maximum_age_raw":"65 years","maximum_age":"65","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:43:41","number_of_arms":"2","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A Phase 1, Open-Label, Drug-Drug Interaction Study Between Methadone and BMS-663068; and Between Buprenorphine/Naloxone and BMS-663068","org_study_id":"206216","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"1","primary_compl_date":"06/29/2016 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Cmax for Methadone (Part 1) and buprenorphine and norbuprenorphine (Part 2)","outcome_time_frame":"Days 1 to 10","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"AUC(TAU) for Methadone (Part 1) and buprenorphine and norbuprenorphine (Part 2)","outcome_time_frame":"Days 1 to 10","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[{"id":"AI438-068","id_type":"Other Identifier","id_domain":"Bristol-Myers Squibb"}],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Incidence of Adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation.","outcome_time_frame":"For AEs, Days 1 to 10; for SAEs, Screening, Days 1 to 10 and up to 30 days post discontinuation of dosing","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GlaxoSmithKline"]},"start_date":"01/12/2016 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":false}},"pageContext":{"studyId":"206216"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}